Perrigo (PRGO)

Retailers are ordering cautiously, yet Perrigo's European health brands grew well ahead of their categories and took share.

Retailer caution and softer Europe weigh; infant formula exit reshapes the portfolio.

Perrigo makes private-label over-the-counter drugs, which sounds like a reliable business, but there are warning signs to consider before you buy it.

Market share gains offset sales decline as Perrigo completes Dermacosmetics divestiture.

Perrigo (NYSE:PRGO) reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving

Perrigo (PRGO) Q1 2026 Earnings Transcript

The highest-yielding healthcare stocks come with some side effects.

Perrigo (PRGO) Q4 2025 Earnings Call Transcript

Which of the highest-yielding healthcare stocks are value traps or golden opportunities?

The utility was enjoying a double-digit gain, but not because of any proprietary news.

Perrigo (PRGO) Q3 2025 Earnings Call Transcript

Perrigo's Q3 2025 results show an earnings beat but a revenue miss. The stock dipped as the company announced a strategic review of its infant formula business.